logo
Plus   Neg
Share
Email

Allergan Says FDA Approves JUVÉDERM VOLLURE XC

Allergan plc. (AGN) said that it has received approval from the U.S. Food and Drug Administration to market JUVÉDERM VOLLURE XC, for correction of moderate to severe facial wrinkles and folds, such as nasolabial folds, in adults over the age of 21. JUVÉDERM VOLLURE XC will be available to physicians in April 2017.

In the US pivotal clinical trial, a majority (59%) of subjects saw improvement in moderate to severe nasolabial folds for up to 18 months. Patient satisfaction in the pivotal study was also high: 82% of patients said they were very satisfied at 6 months and 68% at 18 months.

The most common side effects seen in the clinical study were temporary injection site responses at the treatment site such as swelling, tenderness, bruising, firmness lumps/bumps, redness, pain, discoloration, and itching. Most of these side effects resolved within 1 week.

JUVÉDERM VOLLURE XC was first approved in Europe as JUVÉDERM VOLIFT in 2013. The JUVÉDERM family of products is marketed and sold in more than 80 countries outside the United States.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Russia's biggest two banks, Sberbank and Alfa Bank, are planning to test several private banking products based on cryptocurrencies in a regulatory sandbox environment hosted by the Russian central bank, the Kommersant newspaper reported. After coming under pressure early in the session, stocks regained some ground over the course of the trading day on Friday. The major averages climbed well off their lows of the session, with the S&P 500 briefly turning positive. President Donald Trump's former campaign chairman Paul Manafort is headed to jail after his bail was revoked by a District Court Judge on Friday. Manafort will remain in jail as he awaits trial on criminal charges related to his lobbying work for a pro-Russia party in Ukraine.
Follow RTT